Seagen Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
2,675
- Stock Symbol
-
SGEN
- Investments
-
5
- Share Price
-
$178.33
- (As of Monday Closing)
Seagen General Information
Description
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Contact Information
Website
www.seagen.com
Formerly Known As
Seattle Genetics, Inc., Seattle Genetics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
- 21717 30th Drive Southeast, Building 3
- Suite 21823
- Bothell, WA 98021
- United States
+1 (425) 000-0000
Seagen Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $178.33 | $175.81 | $105.43 - $192.79 | $32.4B | 184M | 1.41M | -$4.04 |
Seagen Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 30,672,803 | 25,892,010 | 29,696,096 | 18,790,185 |
| Revenue | 1,777,873 | 1,574,371 | 2,175,536 | 916,713 |
| EBITDA | (658,002) | (597,079) | 679,085 | (125,136) |
| Net Income | (739,796) | (674,471) | 613,670 | (158,650) |
| Total Assets | 3,630,343 | 3,719,604 | 4,000,906 | 2,205,866 |
| Total Debt | 50,205 | 56,665 | 61,884 | 77,052 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Seagen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Seagen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Seagen Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancer
Drug Discovery
Bothell, WA
2,675
As of 2021
00.000
000000&0
000000
boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000 000000000
Alameda, CA
000
As of 0000
00000
000000000
00000
00000
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non p
0000 00000000
South San Francisco, CA
000
As of 0000
00000
000000 - 000
00000
Add Comparison
Seagen Competitors (50)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exelixis | Formerly VC-backed | Alameda, CA | 000 | 00000 | 000000000 | 00000 |
| 00000 000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
| 000000000 | Formerly PE-Backed | Planegg, Germany | 000 | 00000 | 000000000 | 00000 |
Seagen Patents
Seagen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210221897-A1 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies | Pending | 30-Dec-2019 | 00000000000 | |
| US-20210228676-A1 | Combination therapy with liv1-adc and pd-1 antagonist | Pending | 09-Dec-2019 | 000000000 | |
| US-20210198367-A1 | Anti-avb6 antibodies and antibody-drug conjugates | Pending | 05-Dec-2019 | 00000000000 | |
| AU-2020381495-A1 | Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate | Pending | 15-Nov-2019 | 0000000000 | |
| US-20210101982-A1 | Anti-pd-l1 antibodies and antibody-drug conjugates | Pending | 04-Oct-2019 | C07K16/2827 |
Seagen Executive Team (17)
Seagen Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alpna Seth Ph.D | Self | Board Member | 000 0000 |
| Clay Siegall Ph.D | Seagen | Co-Founder, President, Chief Executive Officer & Chairman of the Board | 000 0000 |
| Daniel Welch | Self | Board Member | 000 0000 |
| David Gryska | Self | Board Member | 000 0000 |
| Felix Baker Ph.D | Self | Chairman of the Board | 000 0000 |
Seagen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Seagen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Seagen Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 24-Mar-2021 | 0000 | 0000 | Drug Discovery | 00000000 |
| 000000000 000 | 09-Mar-2018 | 0000000000 | 00000 | Biotechnology | 0000 0000 |
| 0000000-00000 | 01-Oct-2017 | 000000000 | 000.00 | Buildings and Property | 0000 0000 |
| 00000 00000 0 | 01-Aug-2017 | 0000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00 |
| Cogent Biosciences | 11-Jun-2015 | Early Stage VC | 0000 | Biotechnology | 0000 0000 |
Seagen Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 24-Mar-2021 | 0000 | 0000 | Completed |
|
| Cogent Biosciences | 11-Jun-2015 | Early Stage VC | 0000 | Completed |
|